Please download and print the PDF file below:

Denise Globe, PhD

Denise Globe, PhD, is Director, Global Health Economics & Outcomes Research, Amgen Inc., Thousand Oaks, CA. She has disclosed that she is a major stock holder of Amgen, Inc.

Deborah Glidden, MSN, ARNP-C, CNN

Deborah Glidden, MSN, ARNP-C, CNN, is Nurse Practitioner, CKD Clinic & Research, Nephrology Associates of Central Florida, PA, Orlando, FL. She is a member of ANNA’s Sunshine Central Chapter.

Joachim Hertel, MD, FACP

Joachim Hertel, MD, FACP, is Staff Physician, Nephrology Associates, PC, Augusta, GA. He has disclosed that he received grant/research support from Amgen, Inc. and is a on the consultant presenter bureau of Amgen, Inc.

Joele Thomas, BSN, RN

Joele Thomas, BSN, RN, is Study Coordinator, Western New England Renal and Transplant Associates, Springfield, MA.

Michele Ackerman, ASN, RN

Michele Ackerman, ASN, RN, is Nurse Manager, Nephrology Associates of Central Florida, PA, Orlando, FL.

Felicia Chidolue, MSN, RN, FNP-C

Felicia Chidolue, MSN, RN, FNP-C, is Sub- Investigator, Study Coordinator, Southwest Houston Research, Houston, TX.

Bianca Blanco, BSN, RN

Bianca Blanco, BSN, RN, is Clinical Research Coordinator, Clinical Research Associates, LLC, Palm Beach Gardens, FL.

Annette Borden, MA

Annette Borden, MA, is Lead Medical Assistant, Western Washington Medical Group – Nephrology, Everett, WA.

Thomas F. Goss, PharmD

Thomas F. Goss, PharmD, is Vice President, Consulting Services, Covance Market Access Services, Inc., Gaithersburg, MD. He disclosed that research funding was provided to Covance Inc. by Amgen, Inc.

Xiao Xu, PhD, RN

Xiao Xu, PhD, RN, is Principal, Consulting Services, Covance Market Access Services, Inc., Gaithersburg, MD. She disclosed that research funding was provided to Covance Inc. by Amgen, Inc.

Reshma Kewalramani, MD

Reshma Kewalramani, MD, is Director, Medical Affairs – Nephrology, Amgen Inc., Thousand Oaks, CA. She has disclosed that she is a major stock holder of Amgen, Inc.

This cross-sectional study measured patient and family member reported treatment and economic burden associated with monthly versus weekly erythropoiesis stimulating protein therapies for anemia in patients with CKD who were not yet on dialysis. The results indicated that compared to a weekly regimen, a monthly regimen saved patients 7 hours and family members 19 hours per month for routine anemia management. The monthly regimen substantially reduced the reported economic and treatment burdens of patient and their family members.